From Nasdaq: 2025-05-07 02:48:00

Hims & Hers Health (NYSE: HIMS) reported impressive Q1 financial results, with adjusted EPS of $0.28 on revenue of $586 million, surpassing estimates. However, Q2 revenue outlook of $540 million fell short, causing a 4% stock decline in after-hours trading. The company aims for $6.5 billion in 2030 sales, focusing on strategic growth initiatives, including partnerships to offer branded medications like Novo Nordisk’s Wegovy.

HIMS stock surged 50% in the past month, driven by its collaboration with Novo Nordisk and a strategic shift towards branded pharmaceuticals. Despite a recent dip, the company’s valuation at $40 presents a price-to-sales ratio of 5.5x, reflecting improved business fundamentals. Long-term investors may find potential entry points amid future price fluctuations.

For investors seeking to diversify and mitigate stock-specific risks, alternative investment strategies like the Trefis RV portfolio or the High-Quality portfolio offer opportunities for strong returns. These strategies have historically outperformed benchmarks, providing upside potential with reduced volatility compared to individual stock investments.



Read more at Nasdaq: What’s Next For HIMS Stock After An Upbeat Q1?